Medicare Enrolled
Dr. Oranus Mohammadi, MD
Medical Oncology · Fresno, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Mohammadi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mohammadi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Mohammadi
Dr. Oranus Mohammadi is a medical oncology specialist in Fresno, CA, with 8 years of NPI registration. Based on federal Medicare data, Dr. Mohammadi performed 1,675 Medicare services across 483 unique beneficiaries.
Between the years covered by Open Payments, Dr. Mohammadi received a total of $5,902 from 43 pharmaceutical and/or device companies across 194 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mohammadi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 8 years in practice
▲ Top 31% volume in CA
$5,902 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,675
Medicare services
Top 31% in CA for medical oncology
483
Unique beneficiaries
$36
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~209 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (Aloxi/palonosetron) | 380 | $1 | $80 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
370 | $0 | $10 |
| Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg | 300 | $42 | $159 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
272 | $103 | $405 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
49 | $110 | $468 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
48 | $24 | $101 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
47 | $72 | $285 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
39 | $28 | $104 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
39 | $142 | $564 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
38 | $13 | $60 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
37 | $1 | $10 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
26 | $1 | $23 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
16 | $104 | $405 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
14 | $12 | $69 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
5.8% high complexity
69.7% medium
24.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,902
Total received (2019-2024)
Avg $1,180/year across 5 years
Top 47% in CA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
43
Companies
194
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,565 (77.3%)
Other
Charitable contributions, space rental, and other categories
$1,237 (21.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$100 (1.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$5,324
2023
$337
2022
$198
2020
$16
2019
$26
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,237
Gilead Sciences, Inc.
$389
GlaxoSmithKline, LLC.
$366
Eisai Inc.
$337
Daiichi Sankyo Inc.
$292
Janssen Biotech, Inc.
$226
PFIZER INC.
$219
Merck Sharp & Dohme LLC
$215
Lilly USA, LLC
$196
PUMA BIOTECHNOLOGY, INC.
$181
Myriad Genetic Laboratories, Inc.
$164
Blueprint Medicines Corporation
$147
Incyte Corporation
$115
Takeda Pharmaceuticals U.S.A., Inc.
$114
ARRAY BIOPHARMA INC
$103
SOBI, INC
$101
Astellas Pharma US Inc
$100
Genentech USA, Inc.
$89
Exelixis Inc.
$87
Pharmacosmos Therapeutics Inc.
$53
TAIHO ONCOLOGY, INC.
$50
ABBVIE INC.
$50
Karyopharm Therapeutics Inc.
$49
Stemline Therapeutics Inc.
$48
Boehringer Ingelheim Pharmaceuticals, Inc.
$44
EMD Serono, Inc.
$42
PharmaEssentia USA Corporation
$31
Sumitomo Pharma America, Inc.
$30
Octapharma USA, Inc.
$30
SpringWorks Therapeutics, Inc.
$27
Genmab U.S., Inc.
$27
Celgene Corporation
$26
Tolmar, Inc.
$25
Ipsen Biopharmaceuticals, Inc
$24
Deciphera Pharmaceuticals Inc.
$24
Biocon Biologics Inc
$23
Coherus Biosciences Inc.
$22
RECORDATI_RARE_DISEASES_INC.
$22
Top 3 companies account for 37.4% of 2024 payments
All-time payments by company (2019-2024) ›
Novartis Pharmaceuticals Corporation
$1,237
Gilead Sciences, Inc.
$529
GlaxoSmithKline, LLC.
$366
Eisai Inc.
$337
Daiichi Sankyo Inc.
$336
PFIZER INC.
$241
Merck Sharp & Dohme LLC
$240
Janssen Biotech, Inc.
$226
Lilly USA, LLC
$196
PUMA BIOTECHNOLOGY, INC.
$181
Myriad Genetic Laboratories, Inc.
$164
Blueprint Medicines Corporation
$147
BeiGene USA, Inc.
$125
Incyte Corporation
$115
Takeda Pharmaceuticals U.S.A., Inc.
$114
ARRAY BIOPHARMA INC
$103
SOBI, INC
$101
Astellas Pharma US Inc
$100
Genentech USA, Inc.
$89
Exelixis Inc.
$87
Amgen Inc.
$73
Seagen Inc.
$68
Pharmacosmos Therapeutics Inc.
$53
TAIHO ONCOLOGY, INC.
$50
ABBVIE INC.
$50
Karyopharm Therapeutics Inc.
$49
Stemline Therapeutics Inc.
$48
Boehringer Ingelheim Pharmaceuticals, Inc.
$44
EMD Serono, Inc.
$42
Ipsen Biopharmaceuticals, Inc
$40
TerSera Therapeutics LLC
$38
PharmaEssentia USA Corporation
$31
Sumitomo Pharma America, Inc.
$30
Octapharma USA, Inc.
$30
SpringWorks Therapeutics, Inc.
$27
Genmab U.S., Inc.
$27
Celgene Corporation
$26
Regeneron Healthcare Solutions, Inc.
$26
Tolmar, Inc.
$25
Deciphera Pharmaceuticals Inc.
$24
Biocon Biologics Inc
$23
Coherus Biosciences Inc.
$22
RECORDATI_RARE_DISEASES_INC.
$22
Top 3 companies account for 36.1% of all-time payments
Associated products mentioned in payments ›
ALUNBRIG · AYVAKIT · Alecensa · BESREMI · BRAFTOVI · BRUKINSA · CABOMETYX · CARVYKTI · DARZALEX · DOPTELET · ELAHERE · ELIGARD · ELREXFIO · EPKINLY · Enhertu · Epkinly · FRUZAQLA · Fabhalta · GILOTRIF · IBRANCE · INJECTAFER · INLYTA · JAKAFI · JEMPERLI · KEYTRUDA · KISQALI · Kadcyla · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · MYCHOICE CDX · MYRISK · NINLARO · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · OJJAARA · ORGOVYX · Ogivri · Onivyde · Orserdu · Phesgo · QINLOCK · REBLOZYL · RYBREVANT · SCEMBLIX · SOMATULINE DEPOT · SYLVANT · SYNAGIS · TECVAYLI · TUKYSA · Trodelvy · Udenyca · VERZENIO · VONJO · XPOVIO · XTANDI · ZEJULA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (77%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
4
Per 100K population
0.4
County median income
$71,434
Nearest hospital
FRESNO SURGICAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Mohammadi is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Mohammadi experienced with anti-nausea injection (aloxi/palonosetron)?
Based on Medicare claims data, Dr. Mohammadi performed 380 anti-nausea injection (aloxi/palonosetron) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mohammadi receive payments from pharmaceutical companies?
Yes. Dr. Mohammadi received a total of $5,902 from 43 companies across 194 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mohammadi's costs compare to other medical oncologists in Fresno?
Dr. Mohammadi's average Medicare payment per service is $36. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mohammadi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Fresno
Browse medical oncologists in Fresno ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in CA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in CA
Which CA medical oncologists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology